ArticleHaematologica2026

Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.

Anna Maria Frustaci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.